Brokerages Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $34.00

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have received an average rating of “Moderate Buy” from the thirteen analysts that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, four have assigned a hold rating and eight have issued a buy rating on the company. The average twelve-month price objective among brokers that have updated their coverage on the stock in the last year is $34.00.

ARCT has been the topic of a number of recent research reports. BTIG Research lowered their price objective on shares of Arcturus Therapeutics from $48.00 to $23.00 and set a “buy” rating on the stock in a report on Wednesday, October 22nd. Roth Mkm started coverage on shares of Arcturus Therapeutics in a research report on Thursday, January 22nd. They issued a “buy” rating and a $20.00 target price for the company. Wells Fargo & Company cut their price target on shares of Arcturus Therapeutics from $42.00 to $20.00 and set an “overweight” rating on the stock in a research report on Thursday, October 23rd. Guggenheim cut Arcturus Therapeutics from a “buy” rating to a “neutral” rating in a report on Wednesday, October 22nd. Finally, Weiss Ratings reiterated a “sell (d-)” rating on shares of Arcturus Therapeutics in a report on Wednesday, January 21st.

Institutional Investors Weigh In On Arcturus Therapeutics

Several large investors have recently made changes to their positions in the stock. Arrowstreet Capital Limited Partnership increased its holdings in Arcturus Therapeutics by 1,371.4% during the third quarter. Arrowstreet Capital Limited Partnership now owns 552,179 shares of the biotechnology company’s stock worth $10,177,000 after buying an additional 514,652 shares during the last quarter. Millennium Management LLC acquired a new stake in Arcturus Therapeutics in the 1st quarter valued at about $4,892,000. Bank of America Corp DE lifted its stake in Arcturus Therapeutics by 112.0% in the 3rd quarter. Bank of America Corp DE now owns 620,055 shares of the biotechnology company’s stock valued at $11,428,000 after purchasing an additional 327,626 shares during the last quarter. Diversify Advisory Services LLC grew its holdings in Arcturus Therapeutics by 1,136.1% during the second quarter. Diversify Advisory Services LLC now owns 222,500 shares of the biotechnology company’s stock worth $2,895,000 after purchasing an additional 204,500 shares during the period. Finally, Hennion & Walsh Asset Management Inc. increased its position in Arcturus Therapeutics by 206.5% during the fourth quarter. Hennion & Walsh Asset Management Inc. now owns 240,303 shares of the biotechnology company’s stock worth $1,473,000 after buying an additional 161,910 shares during the last quarter. Institutional investors and hedge funds own 94.54% of the company’s stock.

Arcturus Therapeutics Price Performance

Shares of Arcturus Therapeutics stock opened at $7.47 on Thursday. The firm has a market cap of $212.22 million, a price-to-earnings ratio of -3.04 and a beta of 2.24. The stock’s 50-day moving average is $6.92 and its 200-day moving average is $12.38. Arcturus Therapeutics has a one year low of $5.85 and a one year high of $24.17.

Arcturus Therapeutics (NASDAQ:ARCT) last posted its quarterly earnings data on Monday, November 10th. The biotechnology company reported ($0.49) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.09) by $0.60. The business had revenue of $17.15 million during the quarter, compared to the consensus estimate of $17.47 million. Arcturus Therapeutics had a negative return on equity of 28.68% and a negative net margin of 68.35%. On average, equities analysts expect that Arcturus Therapeutics will post -2.22 EPS for the current year.

About Arcturus Therapeutics

Arcturus Therapeutics Holdings Inc is a clinical-stage biotechnology company dedicated to developing messenger RNA (mRNA) medicines that address a range of diseases. The company leverages its proprietary STARR® mRNA platform to enable precise control over mRNA expression, supported by its lipid nanoparticle delivery technology, LUNAR®. Arcturus’s approach is designed to address both therapeutic and prophylactic applications, with an emphasis on vaccines and treatments for rare genetic and infectious diseases.

The company’s pipeline includes ARCT-810, an mRNA therapeutic candidate for phenylketonuria (PKU), and ARCT-021 (also known as LUNAR-COV19), a COVID-19 vaccine candidate developed in collaboration with Duke-NUS Medical School in Singapore.